Home
Stock Ideas
Long Ideas
Healthcare
Summary
BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap.
BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera.
Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.
With 70%+ gross margins, disciplined cost controls, and robust volume growth, I rate BLLN a 'Buy' despite competitive risks and a narrow moat.
Alistair Berg/DigitalVision via Getty Images
While the emerging molecular diagnostics field has been dominated by several specialized leaders—think the likes of Natera ( NTRA ), Guardant Health ( GH ), Illumina ( ILMN ), Quest Diagnostics ( DGX ), and
Analyst’s Disclosure: I/we have a beneficial long position in the shares of GH either through stock ownership, options, or…